How to Find Out What Type of Kidney Stone You Have: Gold-Standard Diagnosis, Metabolic Evaluation, and Patient-Informed Prevention by Ori Scott M.Sc. Nutrition, RD.
- orialexscott
- 3 days ago
- 12 min read
A Patient-Centered Scientific Review for Shared Decision-Making With a Urologist, Nephrologist, and Registered Dietitian
Purpose
Kidney stone disease, or urolithiasis/nephrolithiasis, is not a single disorder. Stones can be composed of different substances and may develop through different metabolic, genetic, infectious, dietary, medication-related, gastrointestinal, or anatomical mechanisms.
Knowing that a person “has kidney stones” is therefore only the beginning of the diagnostic process.
For prevention, an important clinical question is:
What is the stone actually made of, and why is this particular person forming it?
This distinction matters because treatment appropriate for one stone phenotype may be ineffective—or occasionally inappropriate—for another. Contemporary guidelines therefore emphasize stone analysis combined with metabolic evaluation, particularly for people with recurrent stones or those at increased risk of recurrence.
The purpose of this review is to help patients understand the diagnostic process so that they can participate in informed, shared decisions with their clinicians. It is educational and is not a substitute for individualized medical assessment.
1. Kidney Stones Are Not All the Same
Major stone categories include:
calcium oxalate;
calcium phosphate;
uric acid;
struvite/infection-related stones;
cystine stones;
ammonium urate stones;
and less common stones including xanthine, 2,8-dihydroxyadenine, and some medication-associated stones.
Mixed-composition stones are also possible.
The European Association of Urology (EAU) emphasizes that stone type is an important determinant of the subsequent diagnostic evaluation.
This is clinically important because knowing the stone composition can substantially change the prevention strategy.
For example, confirmed uric acid stones may sometimes be dissolved through medically supervised urinary alkalinization. Calcium oxalate stones do not have an equivalent established oral dissolution treatment. Therefore, attempting to treat every kidney stone with the same diet, supplement, or medication is not evidence-based.
The supplied literature similarly emphasizes that medical nutrition therapy should be based on confirmed or probable stone composition and metabolic evaluation rather than a universal “kidney stone diet.”
2. Gold Standard: Analyze the Actual Stone
Stone analysis provides the most direct answer to “What type of stone do I have?”
If a stone or stone fragment can be retrieved, laboratory analysis is the preferred way of establishing its composition.
The EAU recommends stone analysis in first-time stone formers using a valid analytical procedure and identifies infrared spectroscopy (IRS/FTIR) or X-ray diffraction (XRD) as preferred methods. Traditional wet chemical analysis is regarded by the EAU as obsolete.
The 2025 CARI Kidney Stones guideline similarly emphasizes stone analysis when stone type is unknown and recommends it for recurrent stone formers.
What should a patient do if a stone is passing?
When medically appropriate, patients can be instructed by their clinical team to filter/strain the urine so that a passed stone or fragment can be collected. The EAU specifically advises patients to filter their urine to retrieve material for analysis.
If a stone is removed during ureteroscopy, percutaneous stone surgery, or another procedure, the patient can ask whether a fragment will be sent to the laboratory for formal stone analysis.
A useful question for the medical team
“Was my stone sent for compositional analysis, and was infrared spectroscopy or X-ray diffraction used?”
Patients should also request and retain a copy of the stone-analysis report for their medical records.
3. Why Looking at a Stone Is Not Enough
The appearance of a stone by itself is not a reliable substitute for validated laboratory analysis.
Likewise, symptoms such as pain location, severity, nausea, or visible blood in the urine cannot reliably establish the chemical composition of a stone.
A laboratory report may identify one dominant material or a mixture of components. That information can subsequently direct a more focused metabolic investigation.
The clinical objective should therefore be:
Stone composition + patient history + blood evaluation + urine evaluation + appropriate imaging
rather than attempting to determine stone type from symptoms alone.
4. Imaging Is Important, but It Does Not Replace Stone Analysis
Imaging determines clinically important characteristics such as:
whether stones are present;
their number;
location;
size;
obstruction;
overall stone burden;
and, with computed tomography, stone density.
Non-contrast computed tomography (CT) can provide clues about composition because different stones may have different radiological characteristics and densities. The EAU notes that non-contrast CT can classify stones according to density, internal structure, and probable composition.
For example, uric acid stones are typically radiolucent on conventional X-ray, whereas calcium-containing stones are generally radiopaque.
However:
Probable composition on imaging is not equivalent to laboratory identification of the retrieved stone.
When stone material is available, it should be analyzed.
5. Stone Composition and the Cause of Stone Formation Are Two Different Questions
This is one of the most important concepts for patients to understand.
Stone analysis asks:“What is this stone made of?”
Metabolic evaluation asks:“Why might this person be forming this type of stone?”
A calcium oxalate stone, for example, does not automatically prove that dietary oxalate is the principal cause.
A person forming calcium stones might instead have abnormalities involving:
low urine volume;
excessive urinary calcium;
low urinary citrate;
excessive urinary oxalate;
high sodium exposure reflected in urine;
altered urinary uric acid;
abnormal urine pH;
gastrointestinal malabsorption;
medication effects;
primary hyperparathyroidism;
renal tubular acidosis;
or, less commonly, inherited metabolic disorders.
Consequently, simply receiving a report stating “calcium oxalate stone” does not complete the evaluation.
6. Basic Medical and Metabolic Evaluation
Current CARI guidance recommends a metabolic evaluation designed to direct individualized prevention. For all stone formers, evaluation includes the history, relevant blood testing, and urine assessment.
Clinical history
The clinician should consider the patient's:
previous stone episodes;
age at first stone;
number and frequency of recurrences;
family history;
medical conditions;
gastrointestinal disease or surgery;
urinary infections;
occupation/environment;
dietary and fluid patterns;
supplements;
prescription and non-prescription medications.
Family history and unusually early stone formation can be especially important when considering inherited disorders.
Blood evaluation
Tests vary according to the clinical situation and guideline used.
The EAU recommends serum evaluation including creatinine, uric acid, calcium, sodium, and potassium, with additional laboratory measurements appropriate to the clinical situation.
NICE specifically recommends measuring serum calcium in adults with renal or ureteric stones because hypercalcaemia may identify an underlying condition such as primary hyperparathyroidism that can be treated.
CARI recommends a broader initial biochemical evaluation that includes calcium, creatinine, electrolytes, urate, phosphate, bicarbonate and other relevant measurements, with parathyroid hormone assessment incorporated into its metabolic evaluation framework.
The precise panel should therefore be individualized by the treating clinician.
7. The 24-Hour Urine Study: Finding the Metabolic Environment That Produces Stones
For recurrent, high-risk, multiple-stone or otherwise appropriate stone formers, 24-hour urine testing is a central component of comprehensive metabolic evaluation.
The American Urological Association (AUA) recommends additional metabolic testing in recurrent stone formers and high-risk or interested first-time stone formers. Its metabolic testing consists of one or two 24-hour urine collections obtained on the person's usual/random diet and analyzed, at minimum, for:
total urine volume;
urine pH;
calcium;
oxalate;
uric acid;
citrate;
sodium;
potassium;
and creatinine.
The AUA panel prefers two collections, although one or two may be obtained.
CARI likewise recommends 24-hour urine assessment in people with recurrent stones, multiple stones, high recurrence risk, or a solitary kidney and recommends two collections where practical because this improves reliability.
Why these measurements matter
The 24-hour urine does not simply determine whether the urine is “normal” or “abnormal.”
It creates a metabolic profile.
For example:
Low urine volume→ increases concentration and supersaturation of stone-forming substances.
High urinary calcium (hypercalciuria)→ can increase calcium-stone risk.
High urinary oxalate (hyperoxaluria)→ can increase calcium oxalate supersaturation.
Low urinary citrate (hypocitraturia)→ removes an important natural inhibitor of calcium crystallization.
Persistently acidic urine→ strongly favors uric acid crystallization.
High urinary sodium→ may contribute to increased urinary calcium and provides useful information about dietary sodium exposure.
Urinary uric acid abnormalities→ can contribute to selected stone phenotypes.
This is why individualized prevention is superior to simply distributing a generic list of foods to avoid.
8. How to Make the 24-Hour Urine Test More Clinically Useful
A technically poor collection can produce misleading results.
Patients should follow the collection laboratory's exact instructions.
CARI advises that the collection should reflect the patient's usual food and fluid intake, rather than temporarily adopting an unusually “healthy” or restrictive diet immediately before testing. Otherwise, the test may fail to represent the metabolic environment in which stones normally develop.
The comprehensive evaluation is generally performed after the acute stone episode has settled and when the person has returned to their usual environment and routine. CARI also notes that collection does not necessarily need to be delayed for stent removal or other urological procedures.
Urinary creatinine can help clinicians assess whether the 24-hour collection was reasonably complete.
9. Urine pH Can Be a Major Diagnostic Clue
Urinary pH deserves particular attention.
Persistently acidic urine strongly favors uric acid crystallization. The EAU considers a 24-hour urine pH below 5.5 hyperacidic and potentially supportive of uric acid crystallization.
Conversely, unusually alkaline urine can occur in other stone-forming conditions and may warrant evaluation for infection or renal tubular acidification disorders depending upon the clinical context.
CARI cautions that ordinary urine dipsticks are insufficiently accurate for some clinical decisions involving stone prevention and recommends appropriate pH measurement devices.
A single urine pH measurement should also not automatically be interpreted as a person's permanent urine pH because urinary pH changes during the day.
10. Urinalysis, Microscopy, and Urine Culture
Urinalysis provides additional diagnostic information.
Testing can identify:
blood;
leukocytes;
nitrites;
urine pH;
specific gravity;
and other abnormalities.
Urine microscopy can occasionally identify characteristic crystals.
The EAU notes that crystals of cystine, 2,8-dihydroxyadenine, and xanthine can provide particularly important diagnostic clues.
If infection is suspected, urine culture is important.
This is especially significant because some stones are associated with urinary infection and require a management strategy fundamentally different from ordinary calcium oxalate prevention.
11. When Cystine or Another Rare Stone Should Be Considered
Rare stone diseases matter because missing the diagnosis may result in years of inappropriate treatment.
Cystine stones arise from cystinuria, an inherited disorder.
Clinical clues that should increase suspicion include:
kidney stones beginning at a young age;
recurrent stone formation;
strong family history;
characteristic crystals;
or stone analysis demonstrating cystine.
CARI recommends consideration of cystine screening when stone composition is unknown and clinical risk factors for cystinuria are present, such as young age at stone formation or a strong family history.
Specialist evaluation may therefore be appropriate when the clinical pattern is unusual.
12. Why the Diagnosis Changes Treatment
The purpose of determining stone composition is not simply to give the stone a name.
It allows stone-specific prevention and treatment.
Calcium oxalate stones
Management is based on the person's urine abnormalities rather than indiscriminate restriction.
Evidence summarized in the supplied review supports adequate hydration, normal dietary calcium rather than routine calcium restriction, reduction of excessive sodium, avoidance of excessive animal-protein intake, targeted reduction of very high oxalate exposure when hyperoxaluria is documented, and avoidance of unnecessary high-dose vitamin C supplementation.
Uric acid stones
Uric acid disease is particularly dependent on urine acidity.
In appropriately selected patients, medically supervised urinary alkalinization—commonly using potassium citrate—can sometimes dissolve existing uric acid stones, not merely prevent new ones.
The supplied evidence review reports that a 2023 systematic review of 1,075 patients undergoing dissolution therapy found complete or partial dissolution in approximately 80% of patients, although protocols and evidence quality varied.
Calcium oxalate stones are different
Current evidence does not demonstrate reliable oral dissolution of established calcium oxalate stones using potassium citrate, magnesium, probiotics, herbs, lemon preparations, or commercial “stone-breaking” supplements.
Potassium citrate may have an important preventive role in appropriately selected calcium-stone formers, particularly in hypocitraturia, but prevention should not be confused with dissolution.
Infection/struvite stones
These require assessment for urinary infection and appropriate urological management rather than dietary treatment alone.
Cystine stones
These require a specialized prevention strategy and often specialist management because the underlying disorder is inherited.
13. Why Patients Should Be Cautious About Generic “Kidney Stone Diets”
A major practical error is beginning an extremely restrictive diet before establishing the stone phenotype and metabolic abnormalities.
For example, calcium restriction was historically attractive because many stones contain calcium.
However, the supplied contemporary evidence review specifically supports normal dietary calcium rather than routine calcium restriction for calcium oxalate stone prevention.
Similarly, restricting every food containing oxalate without evidence of hyperoxaluria can create an unnecessarily restrictive diet.
The scientifically stronger approach is:
identify the stone → identify the metabolic abnormalities → target those abnormalities → repeat measurements to assess response.
14. Repeat Evaluation Matters
Kidney stone prevention is not necessarily a one-time diagnostic process.
The EAU recommends repeat stone analysis when:
stones recur despite pharmacological prevention;
there is early recurrence after apparently complete stone clearance;
or stones recur after a prolonged stone-free interval.
The reason is important: stone composition can change.
CARI similarly notes that stone composition may change over time or following treatment and recommends considering repeat analysis when recurrence is unusual or preventive treatment is not producing the expected response.
Follow-up urine testing can also determine whether treatment has actually changed the targeted urinary abnormality.
15. A Practical Patient Checklist
After a kidney-stone episode, a patient can discuss the following questions with the treating clinician:
Can I collect or strain my urine to retrieve the stone?
If a stone was surgically removed, was a fragment sent for formal analysis?
What is the exact stone composition?
Ask for the percentages/components rather than only “calcium stone.”
What laboratory method was used?
Ideally, validated infrared spectroscopy or X-ray diffraction.
Can I have a copy of the stone-analysis report?
Do my imaging studies show one stone or multiple stones, and are stones present in both kidneys?
Do I need a metabolic evaluation?
Have serum calcium and kidney function been assessed?
Is there a reason to investigate parathyroid hormone, uric acid, bicarbonate/electrolytes, or another metabolic disorder?
Should I have one or preferably two 24-hour urine collections?
What are my urine volume, calcium, oxalate, citrate, uric acid, sodium, pH, and creatinine results?
What specific abnormality are we trying to treat?
How will we measure whether the treatment is working?
When should my urine, blood tests, imaging, or stone analysis be repeated?
Would consultation with a urologist, nephrologist, or renal-specialist registered dietitian improve my prevention plan?
16. When Kidney Stones Require Urgent Medical Attention
Metabolic prevention should never delay treatment of an acute complication.
Urgent medical assessment is particularly important when suspected kidney stones occur with:
fever, chills, or suspected urinary infection;
inability to urinate;
persistent vomiting or significant dehydration;
severe or uncontrolled pain;
worsening kidney function;
known or suspected significant urinary obstruction;
or obstruction affecting a solitary functioning kidney.
An infected obstructed urinary system can constitute a medical/urological emergency.
The supplied evidence review likewise emphasizes immediate medical assessment for fever/suspected infection, inability to urinate, uncontrolled pain, persistent vomiting/dehydration, acute kidney-function deterioration, or clinically important obstruction.
17. The Best-Practice Diagnostic Pathway
A scientifically defensible pathway can be summarized as:
Kidney stone identified
↓
Retrieve the stone whenever possible
↓
Analyze the actual stone with validated methodology(FTIR/infrared spectroscopy or X-ray diffraction)
↓
Document exact stone composition
↓
Review imaging and complete clinical/family/dietary/medication history
↓
Perform basic blood and urine evaluation
↓
Assess recurrence risk
↓
For recurrent/high-risk or otherwise appropriate patients: comprehensive metabolic evaluation, usually including 24-hour urine testing
↓
Identify the dominant modifiable urinary abnormalities
↓
Choose stone-specific nutrition, fluid, medication and/or urological treatment
↓
Repeat appropriate testing to determine whether the intervention actually corrected the targeted risk factor
This is substantially more informative than simply being told to “drink more water” or “avoid oxalate.”
18. Understanding the Limits of Testing
Even excellent testing does not always identify one simple cause.
Kidney stone formation is often multifactorial.
A patient may simultaneously have low urine volume, high urinary sodium, hypercalciuria, hypocitraturia and dietary or metabolic factors contributing to supersaturation.
Similarly, stone composition tells clinicians what formed, whereas 24-hour urine and blood evaluation help explain why the biochemical environment favors its formation.
Neither should automatically be treated as a substitute for the other.
19. Shared Decision-Making
The goal of patient education is not self-treatment.
The goal is to enable a patient to participate meaningfully in decisions with qualified clinicians.
A well-informed patient should be able to ask:
“What type of stone do I have?”
“How was that established?”
“What does my metabolic evaluation show?”
“Which abnormality are we treating?”
“What evidence supports this treatment for my particular stone type?”
“How will we know whether treatment is working?”
Those questions move kidney-stone care from generic advice toward individualized secondary prevention.
Conclusion
The most reliable strategy for determining kidney-stone type is to retrieve and directly analyze the stone whenever possible using a validated laboratory technique such as infrared spectroscopy or X-ray diffraction.
However, identifying stone composition is only one part of modern stone prevention.
Best practice combines:
1. Stone analysis — What is the stone made of?
2. Imaging — Where is it, how large is it, and what is the total stone burden?
3. Clinical assessment — What medical, genetic, gastrointestinal, infectious, medication, occupational, and dietary factors may contribute?
4. Blood testing — Is there an underlying metabolic or systemic disorder?
5. Urine evaluation — What biochemical environment is promoting crystallization?
6. 24-hour urine testing when indicated — Which modifiable urinary risk factors should treatment target?
7. Individualized prevention — Nutrition, fluid intake, medications, and urological management should be selected according to the patient's actual stone phenotype and metabolic findings.
8. Follow-up testing — Prevention should be evaluated objectively rather than assumed to be effective.
The central patient-safety message is simple:
Do not assume the type or cause of a kidney stone from symptoms, appearance, internet lists, or a generic “kidney stone diet.” Whenever possible, determine the stone composition and investigate the metabolic environment that produced it before designing long-term preventive treatment.
Bibliography
European Association of Urology. EAU Guidelines on Urolithiasis. Arnhem, The Netherlands: EAU Guidelines Office; 2026. Sections: Diagnostic Evaluation; Metabolic Evaluation and Recurrence Prevention.
CARI Guidelines Kidney Stones Working Group. Metabolic Evaluation for Prevention of Kidney Stones. Caring for Australasians with Renal Impairment (CARI Guidelines); 2025–2026.
Pearle MS, Goldfarb DS, Assimos DG, et al. Medical Management of Kidney Stones: AUA Guideline. American Urological Association. Published 2014; validity confirmed 2019.
National Institute for Health and Care Excellence (NICE). Renal and ureteric stones: assessment and management. NICE Guideline NG118. London: NICE; 2019.
National Institute for Health and Care Excellence (NICE). Renal and ureteric stones: Quality Standard QS195 — Quality statement 4: Metabolic testing. London: NICE; 2020.
Ong A, Brown G, Tokas T, Hameed BMZ, Philip J, Somani BK. Selection and outcomes for dissolution therapy in uric acid stones: a systematic review of literature. Current Urology Reports. 2023;24(8):355–363. doi:10.1007/s11934-023-01164-7.
Veronese N, Ciriminna S, Errera CM, et al. Preventing and treating kidney stones: an umbrella review of meta-analyses of non-surgical randomized controlled trials. Minerva Urology and Nephrology. 2025;77(4):472–478. doi:10.23736/S2724-6051.25.06296-2.
Medical Nutrition Therapy and the Potential Role of Supplements in Calcium Oxalate and Uric Acid Nephrolithiasis: A Narrative Review of Recent Evidence. Supplied reference document. The review emphasizes stone-specific metabolic evaluation, individualized medical nutrition therapy, and the distinction between prevention and stone dissolution.
Comments